Our team is heading to #AMPath24 to present the largest study to date on the use of mNGS cerebrospinal fluid testing. The data show mNGS testing identified 34% more pathogens than all other direct-detection methods combined. Read more: https://lnkd.in/g9nfkhxn
Delve Bio
生物技术研究
Boston，MA 9,580 位关注者
Providing Molecular Insights for the Precision Care of the Sickest Patients
关于我们
We are a well-funded stealth biotech company backed by some of the most experienced operators and investors in the biotech industry. Our co-founders are highly experienced researchers, clinicians, and entrepreneurs, on a mission to improve precision medicine with cutting-edge genomic technology.
- 网站
-
https://www.delve.bio/
Delve Bio的外部链接
- 所属行业
- 生物技术研究
- 规模
- 2-10 人
- 总部
- Boston，MA
- 类型
- 私人持股
- 创立
- 2022
地点
-
主要
获取路线
US，MA，Boston，02118
Delve Bio员工
动态
-
Data published today in Nature Medicine from more than 4,800 patients who received mNGS testing found nearly 22% of infections were identified through mNGS testing alone, delivering greater diagnostic yield than other microbiological tests. Proud to partner with UCSF on the publication of this important study. https://lnkd.in/gnDi4nPW
Seven-year performance of a clinical metagenomic next-generation sequencing test for diagnosis of central nervous system infections - Nature Medicine
nature.com
-
We're excited to announce our partnership with the world-class team at?Broad Clinical Labs?to scale up access to mNGS testing for patients with serious neurological infections. Together we'll bring?expertise, scalability, and efficiency to deliver an mNGS infectious disease testing service that offers faster answers for patients.?#genomics #biotech #infectiousdisease https://lnkd.in/gyg5eipd
Delve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)
businesswire.com
-
We're #hiring a new Sr. Staff Accountant in United States. Apply today or share this post with your network.
-
Headed to ASM's CVS meeting in October this year? Come join Delve for dinner and discussion on the clinical utility of metagenomics! Contact us for details! (Go to 'Learn More' at www.delve.bio)
-
We're #hiring a new Senior Infrastructure Engineer in Massachusetts. Apply today or share this post with your network.
-
Read about how mNGS has shifted the tide in diagnosing meningitis and encephalitis, where the cause of up to 60% of cases remains unknown. Charles Chiu https://lnkd.in/gMxHn72s
Picture of clinical metagenomic NGS comes into view
https://www.captodayonline.com
-
Come listen to our co-founder, Michael Wilson and Encephalitis International discuss the difficulties in diagnosing encephalitis and how new technologies can help patients get to answers faster. https://lnkd.in/gWWDuZdY
The Encephalitis Podcast Ep 37 - Metagenomics and encephalitis
https://www.youtube.com/
-
Looking to join an awesome, driven, world-class team, delivering a product that has the power to dramatically alter a patient's prognosis? Come join us and learn how Delve Bio is transforming how diseases are detected! https://lnkd.in/gKVKAa3M
-
In a 7-year, real-world data analysis of CNS infections (n=>4800) at UCSF, nearly 22% of cases were diagnosed by metagenomics (mNGS) alone, with over 440 unique pathogen species detected. https://lnkd.in/gpY6A2Z8
Delve Bio Announces Clinical Data on the Use of Metagenomic Next-Generation Sequencing (mNGS) to Identify Pathogens Causing Central Nervous System Infections | BioSpace
biospace.com